-
LentiGlobin Gene Therapy for SCD Given Prime Medicines Status by EMA
LentiGlobin received priority medicines designation by the European Medicines Agency for the treatment of sickle cell disease. Read more about it here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.